

## Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma

Silvia Zibellini,<sup>1</sup> Daniela Capello,<sup>2</sup> Francesco Forconi,<sup>3</sup> Paolo Marcatili,<sup>4</sup> Davide Rossi,<sup>2</sup> Sara Rattotti,<sup>1</sup> Silvia Franceschetti,<sup>2</sup> Elisa Sozzi,<sup>3</sup> Emanuele Cencini,<sup>3</sup> Roberto Marasca,<sup>5</sup> Luca Baldini,<sup>6</sup> Alessandra Tucci,<sup>7</sup> Francesco Bertoni,<sup>8</sup> Francesco Passamonti,<sup>1</sup> Ester Orlandi,<sup>1</sup> Marzia Varettoni,<sup>1</sup> Michele Merli,<sup>1</sup> Silvia Rizzi,<sup>1</sup> Valter Gattei,<sup>9</sup> Anna Tramontano,<sup>4</sup> Marco Paulli,<sup>9</sup> Gianluca Gaidano,<sup>2</sup> and Luca Arcaini<sup>1</sup>

<sup>1</sup>Division of Hematology, Department of Oncohematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Italy;  
<sup>2</sup>Division of Hematology, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; <sup>3</sup>Division of Hematology, University of Siena, Siena, Italy; <sup>4</sup>Department of Biochemical Sciences and Istituto Pasteur Fondazione Cenci Bolognetti, Sapienza University, Roma, Italy; <sup>5</sup>Division of Hematology, University of Modena and Reggio Emilia, Modena, Italy; <sup>6</sup>Division of Hematology, Fondazione IRCCS Ospedale Maggiore Policlinico, University of Milano, Milano, Italy; <sup>7</sup>Division of Hematology, Spedali Civili, Brescia, Italy;  
<sup>8</sup>Laboratory of Experimental Oncology and Lymphoma Unit, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland; <sup>9</sup>Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, IRCCS, Aviano; <sup>10</sup>Department of Pathology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Italy

*Citation:* Zibellini S, Capello D, Forconi F, Marcatili P, Rossi D, Rattotti S, Franceschetti S, Sozzi E, Cencini E, Marasca R, Baldini L, Tucci A, Bertoni F, Passamonti F, Orlandi E, Varettoni M, Merli M, Rizzi S, Gattei V, Tramontano A, Paulli M, Gaidano G, and Arcaini L. Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. *Haematologica* 2010; 95(10):1792-1796.  
*doi:10.3324/haematol.2010.025437*

**Online Supplementary Table S1.** Categories of 4,414 productive, non-redundant HCDR3 sequences used for cluster analysis. A collection of 6,245 IGHV-D-J sequences was retrieved from public nucleotide databases (EMBL, NCBI, IMGT/LIGM-DB; 5,205 sequences) and from our in-house databases (1,040 sequences) and subsequently analyzed by IMGT tools. Redundant and non-functional sequences, as well as sequences from clonally related cells, were excluded to obtain a final database of 4,414 unique HCDR3 amino acid sequences available for the analysis.

Category	N.
CLL	3,197
B-cell malignancies	1,217
SMZL <sup>1-6</sup>	86
MZL excluded SMZL	65
BL	47
DLBCL	60
FL	121
MCL	55
NHL nos	80
HL	160
MM	221
HIV-related NHL	225
PTLD	97

NHL: non-Hodgkin's lymphomas, SMZL: splenic marginal zone lymphoma, MZL: marginal zone lymphoma, BL: Burkitt's lymphoma, DLBCL: diffuse large B-cell lymphoma, FL: follicular lymphoma, MCL: mantle cell lymphoma, HL: Hodgkin's lymphoma, MM: multiple myeloma, PTLD: posttransplant lymphoproliferative disorders

**Online Supplementary Table S2.** Clinical features of 133 patients with splenic marginal zone lymphoma.

Clinical feature	N.	%	N. not available
Male/female	54/79	41/59	0
Age > 60 years	88	66	0
Bone marrow involvement	128	96	0
Leukemic disease	90	68	0
Villous lymphocytes	59	44	0
Villous lymphocytes > 10%	35	26	0
B symptoms	21	16	0
Hemoglobin < 12 g/dL	48	44	25
Platelet count < 100,000/ $\mu$ L	24	22	25
LDH level higher than normal	39	32	13
Albumin < 3.5 g/dL	7	7	41
Serum monoclonal component	42	39	26
Autoimmune background	20	18	24
HCV serology positive	26	20	6
SMZL IIL score <sup>7</sup>	91	-	42
Low risk	42	46	
Intermediate risk	28	31	
High risk	21	23	

**Online Supplementary Table S3.** See file Excel attached.

**Online Supplementary Table S4.** HCV serology according to groups of HCDR3 clustering.

HCDR3 cluster groups	N. of HCV-negative cases (%)	N. of HCV-positive cases (%)
SMZL cluster	9 (100)	0
CLL cluster	5 (100)	0
NHL cluster	1 (33)	2 (67)
Non-clustered cases	86 (78)	24 (22)

## References

1. Bahler DW, Pindzola JA, Swerdlow SH. Splenic marginal zone lymphomas appear to originate from different B cell types. Am J Pathol. 2002;161(1):81-8.
2. Dunn-Walters DK, Boursier L, Spencer J, Isaacs PG. Analysis of immunoglobulin genes in splenic marginal zone lymphoma suggests ongoing mutation. Hum Pathol. 1998;29(6):585-93.
3. Stamatopoulos K, Belessi C, Papadaki T, Kalagiakou E, Stavroyianni N, Douka V, et al. Immunoglobulin heavy- and light-chain repertoire in splenic marginal zone lymphoma. Mol Med. 2004;10(7-12):89-95.
4. Tierens A, Delabie J, Pittaluga S, Driessens A, DeWolf-Peeters C. Mutation analysis of the rearranged immunoglobulin heavy chain genes of marginal zone cell lymphomas indicates an origin from different marginal zone B lymphocyte subsets. Blood. 1998;91(7):2381-6.
5. Zhu D, Orchard J, Oscier DG, Wright DH, Stevenson FK. V(H) gene analysis of splenic marginal zone lymphomas reveals diversity in mutational status and initiation of somatic mutation in vivo. Blood. 2002;100(7):2659-61.
6. Zhu D, Oscier DG, Stevenson FK. Splenic lymphoma with villous lymphocytes involves B cells with extensively mutated Ig heavy chain variable region genes. Blood. 1995;85(6):1603-7.
7. Arcaini L, Lazzarino M, Colombo N, Burcheri S, Boveri E, Paulli M, et al. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood. 2006;107(12):4643-9.
8. Marasca R, Vaccari P, Luppi M, Zucchini P, Castelli I, Barozzi P, Cuoghi A, Torelli G. Immunoglobulin gene mutations and frequent use of VH1-69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B-cell lymphoma. Am J Pathol. 2001;159(1):253-61.
9. De Re V, De Vita S, Marzotto A, Rupolo M, Gloghini A, Pivetta B, Gasparotto D, Carbone A, Boiocchi M. Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus-associated non-Hodgkin lymphomas suggests that the malignant cells are derived from the rheumatoid factor-producing cells that occur mainly in type II cryoglobulinemia. Blood. 2000;96(10):3578-84.
10. Malumbres R, Davis J, Ruiz P, Lossos IS. Somatically mutated immunoglobulin IGHV@ genes without intraclonal heterogeneity indicate a postgerminal centre origin of primary intraocular diffuse large B-cell lymphomas. Br J Haematol. 2007;138(6):749-55.
11. Bende RJ, Aarts WM, Riedl RG, de Jong D, Pals ST, van Noesel CJ. Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. J Exp Med. 2005;201(8):1229-41.
12. Miklos JA, Swerdlow SH, Bahler DW. Salivary gland mucosa-associated lymphoid tissue lymphoma immunoglobulin V(H) genes show frequent use of V1-69 with distinctive CDR3 features. Blood. 2000;95(12):3878-84.
13. Bahler D.W. and Swerdlow S.H. Clonal salivary gland infiltrates associated with myoepithelial sialadenitis (Sjögren's syndrome) begin as non-malignant antigen-selected expansions. Blood. 1998;91(6):1864-72.
14. Sansonno D, Lauletta G, De Re V, Tucci FA, Gatti P, Racanelli V, Boiocchi M, Dammacco F. Intrahepatic B cell clonal expansions and extrahepatic manifestations of chronic HCV infection. Eur J Immunol. 2004;34(1):126-36.
15. Murray F, Darzentas N, Hadzidimitriou A, Tobin G, Boudjouga M, Scielzo C, et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood. 2008;111(3):1524-33.
16. Tierens A, Delabie J, Malecka A, Wang J, Gruszka-Westwood A, Catovsky D, et al. Splenic marginal zone lymphoma with villous lymphocytes shows on-going immunoglobulin gene mutations. Am J Pathol. 2003;162(2):681-9.
17. Messmer BT, Albesiano E, Efremov DG, Ghiootto F, Allen SL, Kolitz J, et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med. 2004;200(4):519-25.
18. Matutes E, Oscier D, Montalban C, Berger F, Callet-Bauchu E, Dogan A, et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia. 2008;22(3):487-95.